Investing.com - Biomarin Pharma (NASDAQ:BMRN) reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Biomarin Pharma announced earnings per share of $-0.04 on revenue of $505.30. Analysts polled by Investing.com anticipated EPS of $-0.02 on revenue of $516.56M.
Biomarin Pharma shares are down 4.3% from the beginning of the year and are trading at $89.78 , down-from-52-week-high.
Biomarin Pharma shares lost 2.52% in after-hours trade the report.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.9B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar